Kite Pharma, Inc. (KITE) stock prices updated...
 

Kite Pharma, Inc. stock price

Kite Pharma, Inc. latest news:


  • 08/28/2017 13:02:05

    Gilead Sciences to buy Kite Pharma for $11.9B to expand cancer drug lineup

    Gilead Sciences to buy Kite Pharma for $11.9B to expand cancer drug lineup        

  • 08/28/2017 13:01:49

    Jim Cramer reacts to the Gilead Sciences-Kite Pharma acquisition

    Gilead Sciences agreed to acquire Kite Pharma for $11.9 billion on Monday, sending shares of both stocks higher. Video provided by TheStreet        

  • 08/28/2017 11:39:53

    Stocks decline as storm pressures insurers and oil companies

    U.S. stocks are rising Monday morning, with health care companies making some of the largest gains after biotechnology company Gilead Sciences agreed to buy cancer drug maker Kite Pharma for $11.9 billion.

  • 08/28/2017 11:37:28

    Gilead to pay $11.9B for cancer treatment developer Kite

    Gilead Sciences is buying Kite Pharma for $11.9 billion, giving the biotechnology company a broader portfolio of potential cell therapies for cancer.

  • 08/28/2017 09:41:09

    Biotech stocks surge on Gilead's Kite Pharma acquisition

    After news of Gilead Sciences Inc.'s about $11 billion acquisition of Kite Pharma Inc. , Juno Therapeutics Inc. shares surged 16.3%, Bluebird Bio Inc. shares surged 9.7% and Cellectis SA ADR shares surged 11.8% in extremely heavy midday trade Monday. The Kite Pharma acquisition marks a large investment by Gilead into a cancer treatment called chimeric antigen receptor T-cell therapy, or CAR-T, which uses a patient's immune T-cells and re-engineers them to better fight cancer. Juno, Bluebird and Cellectis are other biotech companies working in CAR-T. BTIF analyst Dane Leone upgraded Juno on Monday, adding, "we continue to be skeptical of JUNO's current competitive positioning, but upgrade our ranking to Neutral from Sell, as there is not a near term catalyst to offset the positive tailwind for the entire CAR T space." Though there has been speculation about Celgene -- which owns about 10% of Juno's current shares outstanding -- acquiring Juno, "we would be surprised" by a full acquisition, Leone said, since "at this juncture with emerging overlap in Multiple Myeloma and third to market status in CD19 hematological malignancies, we struggle to find a rationale for Celgene wanting to fully own Juno." Kite Pharma shares surged 28% in extremely heavy morning trade. Shares have surged 144% over the last three months, compared with a 1% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    KLA-Tencor CorporationKLAC | KLX Inc.KLXI | Kona Grill, Inc.KONA | KongZhong CorporationKZ | Kopin CorporationKOPN | Kornit Digital Ltd.KRNT | Koss CorporationKOSS | KraneShares CSI China Internet ETFKWEB | Kratos Defense & Security Solutions, Inc.KTOS | Ku6 Media Co., Ltd.KUTV |